Schizophrenia can be found in approximately 1.1% of the world’s population, regardless of racial, ethnic or economic background, and approximately 3.5 million people in the United States are diagnosed with schizophrenia. Unfortunately, individuals with
schizophrenia are prone to premature death, with life expectancy ranging from 14 years to 25 years shorter than the general population.
Patients with psychosis are frequently exposed to negative stereotypes, stigma and social exclusion associated with their diagnosis. In order to break this stigma, better scientific understanding of the causes and nature of schizophrenia is necessary.
On June 28, 2018 in Rayburn 2103 at 12:00pm, the Schizophrenia and Related Disorders Alliance of American (SARDAA) will present a Scientific Legislative Briefing presenting neurological evidence of schizophrenia and anosognosia. Founded a decade ago, the
Schizophrenia and Related Disorders Alliance of America promotes improvement in lives affected by schizophrenia-related brain illnesses (mental illnesses involving psychosis). SARDAA promotes hope and recovery through support programs, education, collaboration, and advocacy.
Come hear an outstanding panel discuss the science behind psychosis in this legislative briefing.
- Daniel Weinberger, MD – Director & CEO, Lieber Institute for Brain Development
- Xavier Amador, PhD – Founder of the LEAP Institute and international anosognosia expert
- Susan Sheena – SARDAA Board Member
- Brandon Staglin – President, One Mind Initiative
Lunch will be served. To RSVP, please contact Bill Judson at firstname.lastname@example.org.
John Culberson Eddie Bernice Johnson
Member of Congress Member of Congress